Orient EuroPharma Co., Ltd.

4120

TW0004120001

Food Processing

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
42.75 ^TWD	0.00%		+0.71%	+9.90%

04-05	Regeneus Ltd announced that it expects to receive AUD 3.481164 million in funding from Zheng Yang Biomedical Technology Co., Ltd., Orient EuroPharma Co., Ltd. and other investors	CI
03-29	Orient EuroPharma Co., Ltd. announced that it expects to receive TWD 300 million in funding	CI

Orient EuroPharma Co., Ltd. announced that it expects to receive TWD 300 million in funding

March 28, 2024

Orient EuroPharma Co., Ltd. announced a private placement to issue 30,000,000 common shares at an issue price of TWD 10 per share for the gross proceeds of TWD 300,000,000 on March 29, 2024. The transaction has been approved by shareholders of the company.

Latest news about Orient EuroPharma Co., Ltd.

Regeneus Ltd announced that it expects to receive AUD 3.481164 million in funding from Zheng Yang Biomedical Technology Co., Ltd., Orient EuroPharma Co., Ltd. and other investors	04-04	CI
Orient EuroPharma Co., Ltd. announced that it expects to receive TWD 300 million in funding	03-28	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Accounting Officer	23-08-10	CI
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Financial Officer	23-08-01	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Orient EuroPharma, OncoVent Sign License Deal	23-03-30	MT
OncoVent Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab	23-03-28	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-24	CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Orient Europharma Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
Orient Europharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-11	CI
Orient Europharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-25	CI
Regent Pacific Group Limited Announces Operation Update on Fortacin	21-01-18	CI
Regent Pacific's Commercial Strategic Partner Receives Approval from Taiwan Food and Drug Administration	20-12-14	CI
Orient Europharma Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Orient Europharma Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-09	CI
Orient Europharma Provides Update on Progress of Approval and Commercialization of Fortacin in Taiwanese, Hong Kong and Macau	20-06-18	CI

Chart Orient EuroPharma Co., Ltd.

Duration

Period

More charts

Company Profile

Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.

Sector

Food Processing

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
ORIENT EUROPHARMA CO., LTD.	+9.90%	114M
ZHEJIANG NHU COMPANY LTD.	+16.80%	8.43B
BELLRING BRANDS, INC.	+7.94%	7.8B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+15.02%	6.82B
BYHEALTH CO., LTD	-6.75%	3.74B
THE SIMPLY GOOD FOODS COMPANY	-4.77%	3.77B
XIAMEN KINGDOMWAY GROUP COMPANY	+4.41%	1.44B
SIRIO PHARMA CO., LTD.	+20.28%	1.04B
USANA HEALTH SCIENCES, INC.	-12.85%	890M
JAMIESON WELLNESS INC.	-15.63%	812M

Special Foods & Wellbeing Products